NDA 020272 · Janssen Pharms
Risperdal
Risperidone · Oral · Atypical Antipsychotic
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1993
Dec 29, 1993
Approved uses
10
Original approval plus efficacy supplements
Registered trials
514
127 Phase 3, 14 recruiting
FAERS reports
121,516
83,453 serious, 9,507 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1) ] WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. RISPERDAL is not approved for use in patients with dementia-related psychosis. ( 5.1 )
What it is approved for
From the label in effect Oct 23, 2026.
RISPERDAL is an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) 1.1 Schizophrenia RISPERDAL (risperidone) is indicated for the treatment of schizophrenia. Efficacy was established in 4 short-term trials in adults, 2 short-term trials in adolescents (ages 13 to 17 years), and one long-term maintenance trial in adults [see Clinical Studies (14.1) ] . 1.2 Bipolar Mania Monotherapy RISPERDAL is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in 2 short-term trials in adults and one short-term trial in children and adolescents (ages 10 to 17 years) [see Clinical Studies (14.2) ] . Adjunctive Therapy RISPERDAL adjunctive therapy with lithium or valproate is indicated for the treatment of acute manic or mixed episodes associated with Bipolar I Disorder. Efficacy was established in one short-term trial in adults [see Clinical Studies (14.3) ] . 1.3 Irritability Associated with Autistic Disorder RISPERDAL is indicated for the treatment of irritability associated with autistic disorder, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods. Efficacy was established in 3 short-term trials in children and adolescents (ages 5 to 17 years) [see Clinical Studies (14.4) ] .
Mechanism: The mechanism of action of risperidone in schizophrenia is unclear. The drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D 2 ) and serotonin Type 2 (5HT 2 ) receptor antagonism. The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone (paliperidone) [see Clinical Pharmacology (12.3) ] . Antagonism at receptors other than D 2 and 5HT 2 may explain some of the other effects of risperidone [see Clinical Pharmacology (12.1) ] .
Therapeutic areas: Psychiatry
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 2, 2012 Supplement 65 · Efficacy LabelLetter
- Aug 22, 2007 Supplement 47 · Efficacy · priority review LabelReviewLetter
- Aug 22, 2007 Supplement 46 · Efficacy · priority review ReviewPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Oct 6, 2006 Supplement 36 · Efficacy · priority review ReviewLabelLetter
- Oct 6, 2006 Supplement 41 · Efficacy · priority review ReviewLabelLetter
- Dec 4, 2003 Supplement 26 · Efficacy LabelReviewLetter
- Dec 4, 2003 Supplement 27 · Efficacy ReviewLetterLabel
- Mar 3, 2002 Supplement 8 · Efficacy ReviewLetter
- Oct 17, 1997 Supplement 7 · Efficacy ReviewOther
- Dec 29, 1993 Original approval · Type 1 - New Molecular Entity · priority review ReviewOther Important Information from FDAPediatric DD Summary Review
7 products under this application
- RISPERDAL · RISPERIDONE 0.25MG · TABLET, ORAL · Prescription · TE AB
- RISPERDAL · RISPERIDONE 4MG · TABLET, ORAL · Prescription · TE AB
- RISPERDAL · RISPERIDONE 2MG · TABLET, ORAL · Prescription · TE AB
- RISPERDAL · RISPERIDONE 0.5MG · TABLET, ORAL · Prescription · TE AB
- RISPERDAL · RISPERIDONE 5MG · TABLET, ORAL · Discontinued
- RISPERDAL · RISPERIDONE 3MG · TABLET, ORAL · Prescription · TE AB
- RISPERDAL · RISPERIDONE 1MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Risperidone" as an intervention, any sponsor and status, largest first.
- Safety Study of Sertindole Versus Risperidone Under Normal Conditions of UsePivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT00856583 · 9,809 participants · Start Jul 2002 · Primary completion Feb 2008
Drug: Sertindole; Risperidone · For: Schizophrenia
- Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Pivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00012558 · 5,000 participants · Start Sep 1998
Drug: lithium; valproate and 6 more · For: Bipolar Disorder
Sites: Stanford, California; Denver, Colorado; Boston, Massachusetts · 11 sites in all
- Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia IndividualsStatus unknown
Tianjin Medical University General HospitalAcademic, hospital or other
NCT03790085 · 2,700 participants (planned) · Start Sep 1, 2018 · Primary completion Jun 30, 2020
Drug: Risperidone; Olanzapine and 1 more · For: Schizophrenia; Major Depressive Disorder; Anxiety Disorders
Sites: Tianjin, China
- Metabolic Profile and Anthropometric Changes in SchizophreniaPivotal-lookingCompleted
Central Institute of Psychiatry, Ranchi, IndiaAcademic, hospital or other
NCT00534183 · 2,006 participants · Start Jun 2006
Drug: Olanzapine; Risperidone and 1 more · For: Metabolic Syndrome; Diabetes; Obesity
Sites: Ranchi, India
- The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With SchizophreniaPivotal-lookingCompleted
Beijing HuiLongGuan HospitalAcademic, hospital or other
NCT04076371 · 1,640 participants · Start Jan 2012 · Primary completion Dec 2018
Drug: olanzapine-sertraline combination; only olanzapine and 6 more · For: Schizophrenia
- CATIE- Schizophrenia TrialPivotal-lookingCompleted
National Institute of Mental Health (NIMH)NIH
NCT00014001 · 1,600 participants · Start Dec 2000
Drug: perphenazine; olanzapine and 5 more · For: Schizophrenia
Sites: Chula Vista, California; Los Angeles, California; Orange, California · 54 sites in all
- A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic SchizophreniaPivotal-lookingCompleted
Janssen, LPJohnson & Johnson (Janssen) (JNJ)
NCT00249119 · 1,579 participants
Drug: risperidone · For: Schizophrenia; Psychotic Disorder
- Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With SchizophreniaPivotal-lookingCompleted
Central South UniversityAcademic, hospital or other
NCT00654576 · 1,400 participants (planned) · Start Feb 2005 · Primary completion Dec 2007
Drug: Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole · For: Schizophrenia
Sites: Changsha, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gynaecomastia24,464
- off label use12,012
- abnormal weight gain9,410
- weight increased8,935
- drug ineffective7,389
- product use in unapproved indication5,942
- emotional disorder5,911
- injury4,618
- drug interaction4,510
- hyperprolactinaemia4,424
- somnolence4,365
- galactorrhoea3,705
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2,082 |
| 2005 | 2,052 |
| 2006 | 2,349 |
| 2007 | 2,212 |
| 2008 | 2,285 |
| 2009 | 3,901 |
| 2010 | 3,696 |
| 2011 | 3,714 |
| 2012 | 3,761 |
| 2013 | 3,058 |
| 2014 | 4,161 |
| 2015 | 12,643 |
| 2016 | 13,493 |
| 2017 | 13,038 |
| 2018 | 6,712 |
| 2019 | 7,593 |
| 2020 | 6,046 |
| 2021 | 4,893 |
| 2022 | 5,329 |
| 2023 | 4,918 |
| 2024 | 5,290 |
| 2025 | 4,848 |
| 2026 | 3,441 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Risperdal (Risperidone)
2024 spending
$3.6M
Beneficiaries
954
6,767 claims
Per beneficiary
$3,817
$7.29 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $11,292,438 |
| 2021 | $9,168,124 |
| 2022 | $4,387,669 |
| 2023 | $4,170,926 |
| 2024 | $3,641,519 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials.
Kishi T, Ikuta T, Matsuda Y, et al. · Mol Psychiatry 2022 · Systematic Review, Research Support, Non-U.S. Gov't
- Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis.
Krause M, Zhu Y, Huhn M, et al. · Eur Arch Psychiatry Clin Neurosci 2018 · Meta-Analysis, Systematic Review
- Antipsychotics for delirium.
Lonergan E, Britton AM, Luxenberg J, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Risperidone in children with autism and serious behavioral problems.
McCracken JT, McGough J, Shah B, et al. · N Engl J Med 2002 · Clinical Trial, Comparative Study
- Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.
Tian J, Siafis S, Lin X, et al. · Eur Neuropsychopharmacol 2025 · Systematic Review, Meta-Analysis
- Pharmacological and non-pharmacological interventions for irritability in autism spectrum disorder: a systematic review and meta-analysis with the GRADE assessment.
Choi H, Kim JH, Yang HS, et al. · Mol Autism 2024 · Meta-Analysis, Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.